Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to investigate anti-tumors efficacy of LIS1 in selected subtypes of Peripheral TCell Lymphoma (PTCL) and to further evaluate its safety and tolerability at RP2D.

Trial Details

NCT ID
NCT06495723
Phase
PHASE1 / PHASE2
Sponsor
Xenothera SAS
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • LIS1
Locations (sample)
  • Caen, France|49.18585,-0.35912
  • Clermont-Ferrand, France|45.77969,3.08682
  • Créteil, France|48.79266,2.46569
  • Pessac, France|44.80565,-0.6324
  • Pierre-Bénite, France|45.70359,4.82424

Key Eligibility Criteria

  • Provide signed, written informed consent.
  • Is male or female, age ≥18 years old (at the time consent is obtained)
  • For Part 1: Has a histological diagnosis of the following relapsed or refractory PTCL based on WHO 2022 classification of lymphoid neoplasms
  • Intestinal T-cell and NK cell lymphoid proliferations and lymphomas (without NK cell neoplasms)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →